Cecil Textbook of Medicine, 20th Edition, vol. 1, pp. 1005-10(1996).* |
Uckum et al, Current Cancer Drug Taegets, 1, 59-71(2001).* |
Liu et al(PubMed 12447698, also cited as Oncogene, 21/54, 8347-50(2002).* |
Granata et al(PubMed 1286405, also cited as Int. Arch. Allergy. Immunol. 131/3, 153-63(2003).* |
Isono Takikita et al(PubMed Abstract 12819032, also cited as Am. J. Pathol. 163/1,277-86(2003).* |
Ding et al(PubMed Abstract 12881526, also cited as J. Biol. Chem. Jul. 24(2003).* |
Burchat, A. F., et al; “Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of Ick II”; Bioorganic & Medicinal Chemistry Letters 10 (2000) 2171-2174. |
Arnold, L. D., et al; “Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of Ick I”; Bioorganic & Medicinal Chemistry Letters 10 (2000) 2167-2170. |
Traxler, P. M.; “Protein tyrosine kinase inhibitors in cancer treatment”; Exp. Opin. Ther. Patents; 1997, 7(6), p 571-588. |
Showalter, H. D. H., et al; “Small Molecule Inhibitors of the Platelet-Derived Growth Factor Receptor, the Fibroblast Growth Factor Receptor, and Src Family Tyrosine Kinases”; Pharmacol. Ther. vol. 76, Nos. 1-3, p 55-71 1997. |
Traxler, P; “Tyrosine kinase inhibitors in cancer treatment (Part II)”;Exp. Opin. Ther. Patents, 1998, 8(12), p 1599-1625. |